LAUSR

[4] of normal tissues. Hescot et al first reported on two To the Editor: Hepatocellular carcinoma (HCC) is the [1] third most lethal malignancy globally. Besides sorafenib, patients who developed irreversible pancreatic atrophy [5] lenvatinib is currently the second approved targeted agent for the first-line treatment of HCC in 2018. Lenvatinib is an oral multikinase inhibitor that targets vascular endothelial growth factor (VEGF) receptors 1 to 3, fibroblast growth factor receptors 1 to 4, platelet-derived growth factor receptor a, RET, and KIT. Patients who received lenvatinib experienced diarrhoea, and alopecia, and more instances of hypertension, proteinuria, and hypothyroidism. Here, we report two patients that developed irreversible pancreatic atrophy as a novel adverse event of lenvatinib.